A discovery alone does not change a life, biotech executive says

For a family, the question is direct: Can this patient access the treatment? Inside a biotechnology company, that request may open several clinical, regulatory and commercial pathways. In conversation with cardiologist Tiago Bignoto, biotechnology executive Dorian Readnour explains why science changes lives only when leadership, clinical expertise and patient experience connect early.

For a physician or family confronting serious disease, access can sound like a single, urgent request: "I just want access for my patient."

Inside a biotechnology company, Dorian Readnour said, the request immediately becomes more complex.

"That is one question to us. That is three, maybe four questions," she said. Is the physician asking about a clinical trial, expanded access or commercial access after approval? Each route involves different teams, evidence, rules and timelines.

The gap helps explain why a breakthrough can be celebrated long before it changes a patient's life. Discovery must become credible evidence; regulators and payers must recognize value; and health systems must be able to deliver the care. A failure at any point can leave families navigating institutions that were never designed around a single patient journey.

Readnour has spent her career at that intersection. With international experience in biotechnology, rare disease, strategy and patient access, she focuses on the decisions required to move a therapy across systems and borders. Bignoto, a cardiologist, echocardiographer and founder of The Valve Club, approaches the same challenge through clinical practice, research and physician education.

Their conclusion is shared: science, execution and patient experience cannot operate as separate stages if the goal is real-world impact.

Readnour described a structural mismatch. Companies organize work through functions and processes while physicians organize it around clinical urgency. Families experience this gap as time that cannot be recovered.

Historically, she said, a request could be passed between departments as each team addressed only its part. A better model creates a clear point of entry and routes the request toward the appropriate pathway — trial, expanded access or commercial access.

The problem is not merely administrative. It is a leadership question: Who is responsible for seeing the patient's entire journey when every institution sees only one segment of it?

That tension helped shape Readnour's career. Her early work in healthcare settings showed her both the value of clinical care and the limits created when organizations lacked the resources or business capability to scale new solutions. She became interested in whether business goals and doing right by families could advance together.

That philosophy changes how an executive defines success. Approval is not the finish line if diagnosis is delayed, physicians are unprepared, reimbursement is unavailable or patients cannot find the right door.

Bignoto's perspective begins earlier in the chain. A promising hypothesis must be tested through rigorous trial design and evidence strong enough to guide care. In rare diseases, inherited cardiovascular conditions and other highly specific populations, patients may be few, centers dispersed and meaningful outcomes years away.

Industry can contribute capital, technical expertise and operational scale. But Readnour and Bignoto argued that investment creates more value when clinical leaders help define the problem before a development plan is fixed.

Physicians can assess whether the right patients can be found, whether an endpoint measures meaningful benefit and whether clinical infrastructure can use an innovation safely. Development and access leaders can explain what evidence regulators and payers will require, where barriers differ and which decisions affect viability at scale.

That is where the role of a key opinion leader, or KOL, becomes more consequential. Bignoto described the KOL not as a prominent name attached to a finished technology, but as an independent scientific bridge connecting development, validation, medical communities and patient care.

For Readnour, such dialogue can expose assumptions that appear coherent inside a corporate plan but fail in practice. The strongest collaboration is not endorsement. It is the willingness to challenge the question, the evidence and the path to implementation while there is still time to change them.

Even a strong development plan can break when it encounters a healthcare system it was not built to understand.

Readnour emphasized local expertise. A centralized model can spread lessons, but the barriers facing patients in São Paulo may differ sharply from those in Moldova. Physicians from Croatia and Australia may recognize common scientific questions while working within different diagnostic, regulatory and reimbursement realities.

Those differences determine access. Local clinicians show where a pathway fails; executive teams must translate those signals into decisions about evidence, partnerships, investment and implementation.

Physician communities can shorten that distance. Bignoto created The Valve Club to connect specialists working in valvular and structural heart disease. Such networks can circulate evidence, compare experience and surface questions that a single institution might miss.

But speed is not a substitute for judgment. As information travels faster, trusted clinical leaders become more important, not less: they must distinguish evidence from enthusiasm and translate research without reducing it to promotion.

Readnour noted that governments, payers, clinicians and families may not value the same outcome. In progressive disease, conventional measures can miss changes that matter profoundly to daily life. A child may lose the ability to walk while preserving upper-limb function, independence or participation remains deeply meaningful.

That is why the patient voice should not be added after data has been collected. It should help determine which questions are asked, which outcomes are measured and which compromises are acceptable.

Readnour said patient stories are among the most effective ways to make unmet need visible in strategic discussions. Data describes the size of a problem; lived experience reveals its consequences. Both are necessary to shape research, services and investment around outcomes that matter beyond a spreadsheet.

The same principle applies to time. Some therapies aim to prevent a loss that might not become visible for years. Natural-history data, registries, biomarkers and trial designs suited to small populations can help identify change earlier without lowering the standard of evidence.

Readnour's view of the next decade begins with earlier diagnosis and education, better measures of effectiveness and greater investment in the next generation of physicians. If knowledge remains concentrated in a few centers, discovery will move faster than the health system's ability to apply it.

Bignoto described the same future as one in which integration becomes routine: "It is a collaborative effort where everyone speaks the same language." Physicians understand research and access; scientists work closer to clinical decisions; executives listen to local signals before global strategies are fixed; and patients participate before success has been narrowly defined.

Technology, including artificial intelligence, may help identify overlooked patients and clinical signals earlier. But its value depends on the system around it — the evidence, professionals, institutions and decisions that turn a signal into care.

At the end of the conversation, Readnour said she and Bignoto had approached the problem from different directions but found that their "goals, aims and hopes are very similar."

That convergence is the work of innovation itself: connecting scientific possibility with the leadership, clinical judgment and local capability required to make it real for a patient.